{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:23:26Z","timestamp":1790922206399,"version":"4.1.0"},"reference-count":268,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Cancer therapy and cancer drug discovery and development have been historically focused on specific cancers (tissue\/organ of origin). However, with advances in molecular biology and multi-omics of cancer, there is a trend to develop pan-cancer therapeutic modalities. In targeted therapy, pan-cancer strategies target common molecular alterations across different cancer types and specific cancer strategies are tailored to the unique biological characteristics of individual tumor types. Each approach offers distinct advantages and limitations, and understanding these differences is critical in the era of precision oncology. Targeting key molecular drivers in cancer has significantly changed drug development, allowing for broad-spectrum therapeutic strategies that address shared oncogenic pathways across various tumor types. Among these drivers, RAS, PCNA, and MDM2 have become critical targets due to their roles in a broad-spectrum of cancer biology, e.g., cell proliferation, survival, and genomic stability. Advances in molecularly guided therapies have led to promising approaches for disrupting these pathways, offering new opportunities for cancer treatment. Despite significant progress in the past, challenges such as drug resistance, tumor heterogeneity, and toxicity remain obstacles to widespread clinical success. This review explores the historical development, current advancements, and future directions of RAS, PCNA, and MDM2-targeted therapies, emphasizing their potential to reshape cancer treatment through pan-cancer approaches using biomarker-driven technologies, combination strategies, and next-generation inhibitors. These advancements pave the way for more effective and durable therapies across a wide range of malignancies.<\/jats:p>","DOI":"10.3389\/fphar.2025.1663766","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T05:43:13Z","timestamp":1760506993000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeting MDM2, RAS, and PCNA for cancer targeted therapy: pan-cancer approaches vs. cancer-specific strategies"],"prefix":"10.3389","volume":"16","author":[{"given":"Wei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Alley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meheret","family":"Tadesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinshi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1158\/1078-0432.CCR-21-1291","article-title":"Co-Targeting of MDM2 and CDK4\/6 with Siremadlin and ribociclib for the treatment of patients with well-differentiated or dedifferentiated liposarcoma: results from a Proof-of-Concept, phase Ib Study","volume":"28","author":"Abdul Razak","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1158\/2159-8290.CD-22-1131","article-title":"Targeted MDM2 degradation reveals a new vulnerability for p53-Inactivated triple-negative breast cancer","volume":"13","author":"Adams","year":"2023","journal-title":"Cancer Discov."},{"key":"B3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.trecan.2020.01.005","article-title":"Hyperprogression and immunotherapy: fact, fiction, or alternative fact?","volume":"6","author":"Adashek","year":"2020","journal-title":"Trends Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1021\/acs.jmedchem.6b01665","article-title":"Discovery of 4-((3\u2032R,4\u2032S,5\u2032R)-6\u2033-Chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2\u2033-oxodispiro[cyclohexane-1,2\u2032-pyrrolidine-3\u2032,3\u2033\u2033-indoline]-5\u2032-carboxamido)bicyclo[2.2.2]octane-1-carboxylic acid (AA-115\/APG-115): a potent and orally active murine double minute 2 (MDM2) inhibitor in clinical development","volume":"60","author":"Aguilar","year":"2017","journal-title":"J. Med. Chem."},{"key":"B5","doi-asserted-by":"publisher","first-page":"19503","DOI":"10.1021\/acs.jmedchem.4c01818","article-title":"Discovery of MD-265: a potent MDM2 degrader that achieves complete tumor regression and improves long-term survival of mice with leukemia","volume":"67","author":"Aguilar","year":"2024","journal-title":"J. Med. Chem."},{"key":"B6","doi-asserted-by":"publisher","first-page":"a031484","DOI":"10.1101\/cshperspect.a031484","article-title":"Posttranslational modifications of RAS proteins","volume":"8","author":"Ahearn","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"7883","DOI":"10.1038\/sj.onc.1205948","article-title":"Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2","volume":"21","author":"Alcock","year":"2002","journal-title":"Oncogene"},{"key":"B8","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/0092-8674(88)90571-5","article-title":"Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes","volume":"53","author":"Almoguera","year":"1988","journal-title":"Cell"},{"key":"B9","doi-asserted-by":"publisher","first-page":"18771","DOI":"10.1074\/jbc.M413387200","article-title":"Mdm2 binds to Nbs1 at sites of DNA damage and regulates double strand break repair","volume":"280","author":"Alt","year":"2005","journal-title":"J. Biol. Chem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1158\/1078-0432.CCR-15-0481","article-title":"Results of the phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia","volume":"22","author":"Andreeff","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1158\/1078-0432.CCR-17-1841","article-title":"Effects of Co-occurring genomic alterations on outcomes in patients with KRAS-Mutant non-small cell lung cancer","volume":"24","author":"Arbour","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.molcel.2018.01.023","article-title":"Mitochondrial MDM2 regulates respiratory complex I activity independently of p53","volume":"69","author":"Arena","year":"2018","journal-title":"Mol. Cell"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.3390\/curroncol31040150","article-title":"KRAS: biology, inhibition, and mechanisms of inhibitor resistance","volume":"31","author":"Ash","year":"2024","journal-title":"Curr. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/s41416-024-02586-x","article-title":"Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors","volume":"130","author":"Baranyi","year":"2024","journal-title":"Br. J. Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1194\/jlr.R500012-JLR200","article-title":"Lipid posttranslational modifications. Farnesyl transferase inhibitors","volume":"47","author":"Basso","year":"2006","journal-title":"J. Lipid Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in advanced solid tumors harboring a KRASG12C mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.3390\/molecules25051211","article-title":"Recent small-molecule inhibitors of the p53-MDM2 protein-protein interaction","volume":"25","author":"Beloglazkina","year":"2020","journal-title":"Molecules"},{"key":"B18","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.molcel.2006.01.012","article-title":"PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis","volume":"21","author":"Bivona","year":"2006","journal-title":"Mol. Cell"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.molcel.2020.05.031","article-title":"Rational cancer treatment combinations: an urgent clinical need","volume":"78","author":"Boshuizen","year":"2020","journal-title":"Mol. Cell"},{"key":"B20","doi-asserted-by":"publisher","first-page":"33812","DOI":"10.1074\/jbc.M112.367839","article-title":"Nuclear-to-cytoplasmic relocalization of the proliferating cell nuclear antigen (PCNA) during differentiation involves a chromosome region maintenance 1 (CRM1)-dependent export and is a prerequisite for PCNA antiapoptotic activity in mature neutrophils","volume":"287","author":"Bouayad","year":"2012","journal-title":"J. Biol. Chem."},{"key":"B21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s11523-024-01055-y","article-title":"Divarasib in the evolving landscape of KRAS G12C inhibitors for NSCLC","volume":"19","author":"Brazel","year":"2024","journal-title":"Target Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e2819","DOI":"10.1371\/journal.pone.0002819","article-title":"Mdm2 induces mono-ubiquitination of FOXO4","volume":"3","author":"Brenkman","year":"2008","journal-title":"PLoS One"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1182\/blood.2023020731","article-title":"The role of the MDM2\/p53 axis in antitumor immune responses","volume":"143","author":"Brummer","year":"2024","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/bs.acr.2021.07.004","article-title":"Not all RAS mutations are equal: a detailed review of the functional diversity of RAS hot spot mutations","volume":"153","author":"Burge","year":"2022","journal-title":"Adv. Cancer Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1007\/s12094-024-03819-4","article-title":"Pan-cancer and multiomics: advanced strategies for diagnosis, prognosis, and therapy in the complex genetic and molecular universe of cancer","volume":"27","author":"Campanharo","year":"2024","journal-title":"Clin. Transl. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.sbi.2021.06.015","article-title":"Post-translational modification of RAS proteins","volume":"71","author":"Campbell","year":"2021","journal-title":"Curr. Opin. Struct. Biol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"240","DOI":"10.2174\/1568009620666200115162814","article-title":"Targeting Proliferating Cell Nuclear Antigen (PCNA) as an effective strategy to inhibit tumor cell proliferation","volume":"20","author":"Cardano","year":"2020","journal-title":"Curr. Cancer Drug Targets"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1038\/s41467-021-23186-w","article-title":"RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis","volume":"12","author":"Carr","year":"2021","journal-title":"Nat. Commun."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.3324\/haematol.2019.219261","article-title":"Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem\/progenitor cells in a murine model","volume":"105","author":"Carter","year":"2020","journal-title":"Haematologica"},{"key":"B30","doi-asserted-by":"publisher","first-page":"eaao3003","DOI":"10.1126\/scitranslmed.aao3003","article-title":"Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia","volume":"10","author":"Carvajal","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"9007","DOI":"10.1200\/jco.2023.41.16_suppl.9007","article-title":"KontRASt-01 update: safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC)","volume":"41","author":"Cassier","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/1947601911408079","article-title":"RAS interaction with PI3K: more than just another effector pathway","volume":"2","author":"Castellano","year":"2011","journal-title":"Genes Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"E3445","DOI":"10.1073\/pnas.1303002110","article-title":"Stapled \u03b1\u2212helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy","volume":"110","author":"Chang","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.chembiol.2022.10.005","article-title":"Targeted degradation of PCNA outperforms stoichiometric inhibition to result in programed cell death","volume":"29","author":"Chang","year":"2022","journal-title":"Cell Chem. Biol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1093\/nar\/24.9.1727","article-title":"A 39 amino acid fragment of the cell cycle regulator p21 is sufficient to bind PCNA and partially inhibit DNA replication in vivo","volume":"24","author":"Chen","year":"1996","journal-title":"Nucleic Acids Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13045-021-01127-w","article-title":"Emerging strategies to target RAS signaling in human cancer therapy","volume":"14","author":"Chen","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"8428","DOI":"10.1021\/acs.jmedchem.3c00302","article-title":"Recent advances in Pro-PROTAC development to address On-Target off-tumor toxicity","volume":"66","author":"Chen","year":"2023","journal-title":"J. Med. Chem."},{"key":"B38","doi-asserted-by":"publisher","first-page":"38795","DOI":"10.1074\/jbc.M508578200","article-title":"Structural details on mdm2-p53 interaction","volume":"280","author":"Chi","year":"2005","journal-title":"J. Biol. Chem."},{"key":"B39","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.molcel.2016.12.020","article-title":"Forging ahead through darkness: PCNA, still the principal conductor at the replication fork","volume":"65","author":"Choe","year":"2017","journal-title":"Mol. Cell"},{"key":"B40","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.bbrc.2019.07.052","article-title":"Mdm2 is required for HDAC3 monoubiquitination and stability","volume":"517","author":"Choi","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1016\/j.jtho.2023.05.013","article-title":"Brief report: severe Sotorasib-Related hepatotoxicity and non-liver adverse events associated with sequential anti-programmed cell death (Ligand)1 and sotorasib therapy in KRAS(G12C)-Mutant lung cancer","volume":"18","author":"Chour","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"3934","DOI":"10.1158\/1538-7445.am2022-3934","article-title":"Abstract 3934: KT-253, a highly potent and selective heterobifunctional MDM2 degrader for the treatment of wildtype p53 tumors with superior potency and differentiated biological activity compared to small molecule inhibitors (SMI)","volume":"82","author":"Chutake","year":"2022","journal-title":"Cancer Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.1038\/s41467-021-25432-7","article-title":"Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity","volume":"12","author":"Cindy Yang","year":"2021","journal-title":"Nat. Commun."},{"key":"B44","doi-asserted-by":"publisher","first-page":"eaay2163","DOI":"10.1126\/scitranslmed.aay2163","article-title":"Targeting MDM2-dependent serine metabolism as a therapeutic strategy for liposarcoma","volume":"12","author":"Ciss\u00e9","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/bs.acr.2021.07.009","article-title":"Pan-RAS inhibitors: hitting multiple RAS isozymes with one stone","volume":"153","author":"Coley","year":"2022","journal-title":"Adv. Cancer Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1101\/gad.352081.124","article-title":"Undruggable KRAS: druggable after all","volume":"39","author":"Cox","year":"2025","journal-title":"Genes Dev."},{"key":"B47","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: mission possible?","volume":"13","author":"Cox","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.3390\/genes12071094","article-title":"The importance of being PI3K in the RAS signaling network","volume":"12","author":"Cuesta","year":"2021","journal-title":"Genes (Basel)"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e70042","DOI":"10.1002\/ddr.70042","article-title":"Current strategies and future dimensions in the development of KRAS inhibitors for targeted anticancer therapy","volume":"86","author":"D'Alessio-Sands","year":"2025","journal-title":"Drug Dev. Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1182\/blood.2022016362","article-title":"Venetoclax and idasanutlin in relapsed\/refractory AML: a nonrandomized, open-label phase 1b trial","volume":"141","author":"Daver","year":"2023","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e00115","DOI":"10.1002\/prp2.115","article-title":"Target validation and structure-activity analysis of a series of novel PCNA inhibitors","volume":"3","author":"Dillehay","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"B52","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1001\/jamaoncol.2019.5367","article-title":"Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis","volume":"6","author":"Duan","year":"2020","journal-title":"JAMA Oncol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.lungcan.2003.09.010","article-title":"MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC)","volume":"43","author":"Dworakowska","year":"2004","journal-title":"Lung Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/j.bmcl.2019.04.030","article-title":"Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: recent progress and future challenges","volume":"29","author":"Edmondson","year":"2019","journal-title":"Bioorg Med. Chem. Lett."},{"key":"B55","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.molcel.2019.02.012","article-title":"MDM2 integrates cellular respiration and apoptotic signaling through NDUFS1 and the mitochondrial network","volume":"74","author":"Elkholi","year":"2019","journal-title":"Mol. Cell"},{"key":"B56","doi-asserted-by":"publisher","first-page":"112342","DOI":"10.1016\/j.yexcr.2020.112342","article-title":"M-Ras is Muscle-Ras, Moderate-Ras, Mineral-Ras, Migration-Ras, and many more-ras","volume":"397","author":"Endo","year":"2020","journal-title":"Exp. Cell Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/j.jtho.2024.06.014","article-title":"Letter regarding clinical utility of circulating tumor DNA in patients with advanced KRASG12C-Mutated NSCLC treated with sotorasib","volume":"19","author":"Ernst","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.ymthe.2023.03.017","article-title":"RAS degraders: the new frontier for RAS-driven cancers","volume":"31","author":"Escher","year":"2023","journal-title":"Mol. Ther."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1002\/j.1460-2075.1991.tb07676.x","article-title":"Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line","volume":"10","author":"Fakharzadeh","year":"1991","journal-title":"EMBO J."},{"key":"B60","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus Panitumumab in refractory colorectal cancer with mutated KRAS G12C","volume":"389","author":"Fakih","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"8945","DOI":"10.1074\/jbc.275.12.8945","article-title":"Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53","volume":"275","author":"Fang","year":"2000","journal-title":"J. Biol. Chem."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e000614","DOI":"10.1136\/esmoopen-2019-000614","article-title":"MDM2\/4 amplification predicts poor response to immune checkpoint inhibitors: a pan-cancer analysis","volume":"5","author":"Fang","year":"","journal-title":"ESMO Open"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.apsb.2020.01.003","article-title":"Small-molecule MDM2\/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives","volume":"10","author":"Fang","year":"","journal-title":"Acta Pharm. Sin. B"},{"key":"B64","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1158\/1078-0432.CCR-18-2076","article-title":"Tumor-associated macrophages as prognostic and predictive biomarkers for postoperative adjuvant chemotherapy in patients with stage II Colon cancer","volume":"25","author":"Feng","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B65","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s000180050273","article-title":"Functions of the MDM2 oncoprotein","volume":"55","author":"Freedman","year":"1999","journal-title":"Cell Mol. Life Sci."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e70104","DOI":"10.1002\/pds.70104","article-title":"Hepatobiliary adverse events associated with the KRAS p.G12C inhibitor sotorasib","volume":"34","author":"Frey","year":"2025","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B67","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1021\/jm990966p","article-title":"Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53","volume":"43","author":"Garcia-Echeverria","year":"2000","journal-title":"J. Med. Chem."},{"key":"B68","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1515\/hsz-2019-0330","article-title":"The Ras switch in structural and historical perspective","volume":"401","author":"Gasper","year":"2019","journal-title":"Biol. Chem."},{"key":"B69","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.1016\/j.bmcl.2015.06.058","article-title":"Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode","volume":"25","author":"Gessier","year":"2015","journal-title":"Bioorg Med. Chem. Lett."},{"key":"B70","doi-asserted-by":"publisher","first-page":"8247","DOI":"10.1073\/pnas.1431613100","article-title":"Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor","volume":"100","author":"Girnita","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B71","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s10637-019-00840-1","article-title":"Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma","volume":"38","author":"Gluck","year":"2020","journal-title":"Invest New Drugs"},{"key":"B72","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3390\/biom10040570","article-title":"Human PCNA structure, function and interactions","volume":"10","author":"Gonz\u00e1lez-Maga\u00f1a","year":"2020","journal-title":"Biomolecules"},{"key":"B74","doi-asserted-by":"publisher","first-page":"TPS11589","DOI":"10.1200\/jco.2022.40.16_suppl.tps11589","article-title":"MANTRA: a randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas","volume":"40","author":"Gounder","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.22.01285","article-title":"A first-in-human phase I Study of Milademetan, an MDM2 inhibitor, in patients with advanced liposarcoma, solid tumors, or lymphomas","volume":"41","author":"Gounder","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"11788","DOI":"10.1073\/pnas.1203789109","article-title":"Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization","volume":"109","author":"Graves","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B77","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3390\/cancers14020289","article-title":"ATX-101, a peptide targeting PCNA, has antitumor efficacy alone or in combination with radiotherapy in murine models of human glioblastoma","volume":"14","author":"Gravina","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B78","doi-asserted-by":"publisher","first-page":"e94773","DOI":"10.1371\/journal.pone.0094773","article-title":"A PCNA-derived cell permeable peptide selectively inhibits neuroblastoma cell growth","volume":"9","author":"Gu","year":"2014","journal-title":"PLoS One"},{"key":"B79","doi-asserted-by":"publisher","first-page":"6053","DOI":"10.1158\/1078-0432.CCR-18-0592","article-title":"The anticancer activity of a first-in-class small-molecule targeting PCNA","volume":"24","author":"Gu","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.3390\/genes14071346","article-title":"Therapeutic targeting of DNA replication stress in cancer","volume":"14","author":"Gu","year":"","journal-title":"Genes (Basel)"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.chembiol.2023.07.001","article-title":"Small molecule targeting of transcription-replication conflict for selective chemotherapy","volume":"30","author":"Gu","year":"","journal-title":"Cell Chem. Biol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/s0092-8674(00)81347-1","article-title":"Structure of the C-terminal region of p21(WAF1\/CIP1) complexed with human PCNA","volume":"87","author":"Gulbis","year":"1996","journal-title":"Cell"},{"key":"B83","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/mc.22793","article-title":"HOXA13 contributes to gastric carcinogenesis through DHRS2 interacting with MDM2 and confers 5-FU resistance by a p53-dependent pathway","volume":"57","author":"Han","year":"2018","journal-title":"Mol. Carcinog."},{"key":"B84","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/2041104b0","article-title":"An unidentified virus which causes the rapid production of tumours in mice","volume":"204","author":"Harvey","year":"1964","journal-title":"Nature"},{"key":"B86","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1158\/2159-8290.CD-11-0104","article-title":"Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay","volume":"1","author":"Herman","year":"2011","journal-title":"Cancer Discov."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.3390\/genes12101556","article-title":"RAS dimers: the novice couple at the RAS-ERK pathway ball","volume":"12","author":"Herrero","year":"2021","journal-title":"Genes (Basel)"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1242\/jcs.182873","article-title":"RAS isoforms and mutations in cancer at a glance","volume":"129","author":"Hobbs","year":"2016","journal-title":"J. Cell Sci."},{"key":"B89","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s0014-5793(97)01480-4","article-title":"Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53","volume":"420","author":"Honda","year":"1997","journal-title":"FEBS Lett."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS(G12C) inhibition with Sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/cbic.201900275","article-title":"Targeting PCNA with peptide mimetics for therapeutic purposes","volume":"21","author":"Horsfall","year":"2020","journal-title":"Chembiochem"},{"key":"B92","doi-asserted-by":"publisher","first-page":"100773","DOI":"10.1016\/j.jbc.2021.100773","article-title":"Unlocking the PIP-box: a peptide library reveals interactions that drive high-affinity binding to human PCNA","volume":"296","author":"Horsfall","year":"2021","journal-title":"J. Biol. Chem."},{"key":"B93","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","article-title":"Pancreatic cancer stroma: an update on therapeutic targeting strategies","volume":"17","author":"Hosein","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.2174\/0118715206358340250121060830","article-title":"Research progress on small molecule inhibitors of MDM2-p53 protein-protein interaction","volume":"25","author":"Hu","year":"2025","journal-title":"Anticancer Agents Med. Chem."},{"key":"B95","first-page":"1499","article-title":"A study of DNA ploidy pattern, proliferation index and PCNA in duodenal carcinoma","volume":"89","author":"Imazu","year":"1992","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"B96","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","article-title":"KRAS inhibitors: resistance drivers and combinatorial strategies","volume":"11","author":"Isermann","year":"2025","journal-title":"Trends Cancer"},{"key":"B97","first-page":"993","article-title":"MDM2, an introduction","volume":"1","author":"Iwakuma","year":"2003","journal-title":"Mol. Cancer Res."},{"key":"B98","doi-asserted-by":"publisher","first-page":"188963","DOI":"10.1016\/j.bbcan.2023.188963","article-title":"New insights into RAS in head and neck cancer","volume":"1878","author":"Jagadeeshan","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"B99","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nchembio.421","article-title":"Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery","volume":"6","author":"Jahnke","year":"2010","journal-title":"Nat. Chem. Biol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/nejmoa2204619","article-title":"Adagrasib in Non\u2013Small-Cell lung cancer harboring a KRAS m12C Mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B101","doi-asserted-by":"publisher","first-page":"e2319492121","DOI":"10.1073\/pnas.2319492121","article-title":"Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS-mutant cancers","volume":"121","author":"Jansen","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B102","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrm2438","article-title":"Ras oncogenes: split personalities","volume":"9","author":"Karnoub","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.3390\/cancers15184570","article-title":"Prognostic biomarkers of cell proliferation in colorectal cancer (CRC): from immunohistochemistry to molecular biology techniques","volume":"15","author":"Kasprzak","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B104","doi-asserted-by":"publisher","first-page":"6403","DOI":"10.1073\/pnas.89.14.6403","article-title":"Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity","volume":"89","author":"Kato","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B105","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","article-title":"Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate","volume":"23","author":"Kato","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1158\/1078-0432.CCR-24-3714","article-title":"In situ RAS:RAF binding correlates with response to KRASG12C inhibitors in KRASG12C-Mutant non-small cell lung cancer","volume":"31","author":"Kato","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"B107","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/CAD.0000000000001587","article-title":"Twelve-month progression-free survival with sotorasib and panitumumab in KRAS G12C mutant metastatic colorectal cancer","volume":"35","author":"Kavgaci","year":"2024","journal-title":"Anticancer Drugs"},{"key":"B108","doi-asserted-by":"publisher","first-page":"5984","DOI":"10.1158\/1078-0432.CCR-18-3399","article-title":"Dual farnesyl and geranylgeranyl transferase inhibitor thwarts mutant KRAS-Driven patient-derived pancreatic tumors","volume":"25","author":"Kazi","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B109","doi-asserted-by":"publisher","first-page":"4147","DOI":"10.1182\/bloodadvances.2021006303","article-title":"Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial","volume":"6","author":"Konopleva","year":"2022","journal-title":"Blood Adv."},{"key":"B110","doi-asserted-by":"publisher","first-page":"11544","DOI":"10.1200\/jco.2023.41.16_suppl.11544","article-title":"Exploratory novel biomarker and resistance mechanism of milademetan, an MDM2 inhibitor, in amplified MDM2 intimal sarcoma from an open-label phase 1b\/2 trial (NCCH1806\/MK004)","volume":"41","author":"Koyama","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/0092-8674(94)90014-0","article-title":"Crystal structure of the eukaryotic DNA polymerase processivity factor PCNA","volume":"79","author":"Krishna","year":"1994","journal-title":"Cell"},{"key":"B112","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41591-023-02717-6","article-title":"Sotorasib with panitumumab in chemotherapy-refractory KRAS(G12C)-mutated colorectal cancer: a phase 1b trial","volume":"30","author":"Kuboki","year":"2024","journal-title":"Nat. Med."},{"key":"B113","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1126\/science.274.5289.948","article-title":"Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain","volume":"274","author":"Kussie","year":"1996","journal-title":"Science"},{"key":"B114","doi-asserted-by":"publisher","first-page":"2101674","DOI":"10.1183\/13993003.01674-2021","article-title":"Prognostic phenotypes of early-stage lung adenocarcinoma","volume":"60","author":"Lamort","year":"2022","journal-title":"Eur. Respir. J."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.4161\/cbt.29692","article-title":"An improved isoprenylcysteine carboxylmethyltransferase inhibitor induces cancer cell death and attenuates tumor growth in vivo","volume":"15","author":"Lau","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"B116","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41388-022-02582-6","article-title":"ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study","volume":"42","author":"Lemech","year":"2023","journal-title":"Oncogene"},{"key":"B117","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41568-020-0262-1","article-title":"p53: 800 million years of evolution and 40 years of discovery","volume":"20","author":"Levine","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"B118","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1021\/acs.jmedchem.8b00909","article-title":"Discovery of MD-224 as a First-in-Class, highly potent, and efficacious proteolysis targeting chimera Murine double minute 2 degrader capable of achieving complete and durable tumor regression","volume":"62","author":"Li","year":"2019","journal-title":"J. Med. Chem."},{"key":"B119","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1097\/CM9.0000000000001192","article-title":"Proliferating cell nuclear antigen (PCNA) overexpression in hepatocellular carcinoma predicts poor prognosis as determined by bioinformatic analysis","volume":"134","author":"Li","year":"2020","journal-title":"Chin. Med. J. Engl."},{"key":"B120","doi-asserted-by":"publisher","first-page":"116506","DOI":"10.1016\/j.ejmech.2024.116506","article-title":"An overview of PROTACs targeting MDM2 as a novel approach for cancer therapy","volume":"272","author":"Li","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"B121","doi-asserted-by":"publisher","first-page":"1571786","DOI":"10.3389\/fphar.2025.1571786","article-title":"Targeting PCNA\/PARP1 axis inhibits the malignant progression of hepatocellular carcinoma","volume":"16","author":"Li","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.3390\/ijms25031555","article-title":"Bioinformatics and experimental validation for identifying biomarkers associated with AMG510 (Sotorasib) resistance in KRAS(G12C)-Mutated lung adenocarcinoma","volume":"25","author":"Lin","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B123","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1158\/1078-0432.CCR-23-1212","article-title":"Facts and hopes in immunotherapy strategies targeting antigens derived from KRAS mutations","volume":"30","author":"Linette","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"B124","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejmech.2019.05.018","article-title":"The past, present and future of potential small-molecule drugs targeting p53-MDM2\/MDMX for cancer therapy","volume":"176","author":"Liu","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"B125","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.3390\/ijms22042008","article-title":"Therapeutic advances in oncology","volume":"22","author":"Liu","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B126","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"B127","first-page":"747","article-title":"Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I","volume":"1","author":"Lobell","year":"2002","journal-title":"Mol. Cancer Ther."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1158\/2159-8290.CD-23-0153","article-title":"The MDM2\u2013p53 antagonist Brigimadlin (BI 907828) in patients with advanced or metastatic solid tumors: results of a phase Ia, First-in-Human, dose-escalation Study","volume":"13","author":"LoRusso","year":"2023","journal-title":"Cancer Discov."},{"key":"B129","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1021\/acs.jmedchem.3c01598","article-title":"A potent SOS1 PROTAC degrader with synergistic efficacy in combination with KRAS(G12C) inhibitor","volume":"67","author":"Lv","year":"2024","journal-title":"J. Med. Chem."},{"key":"B130","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1158\/1535-7163.MCT-12-0650","article-title":"Targeted degradation of KRAS by an engineered ubiquitin ligase suppresses pancreatic cancer cell growth in vitro and in vivo","volume":"12","author":"Ma","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"B131","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1242\/jcs.00653","article-title":"Proliferating cell nuclear antigen (PCNA): a dancer with many partners","volume":"116","author":"Maga","year":"2003","journal-title":"J. Cell Sci."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.ccell.2023.07.002","article-title":"KRAS(G12D) inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8(+) T cells","volume":"41","author":"Mahadevan","year":"2023","journal-title":"Cancer Cell"},{"key":"B133","doi-asserted-by":"publisher","first-page":"19472","DOI":"10.1073\/pnas.0604614103","article-title":"A cancer-associated PCNA expressed in breast cancer has implications as a potential biomarker","volume":"103","author":"Malkas","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B134","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/yea.1756","article-title":"Chemical inhibition of CaaX protease activity disrupts yeast Ras localization","volume":"27","author":"Manandhar","year":"2010","journal-title":"Yeast"},{"key":"B135","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.semcancer.2018.01.017","article-title":"Blocking Ras inhibition as an antitumor strategy","volume":"54","author":"Mar\u00edn-Ramos","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1182\/bloodadvances.2021006043","article-title":"The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study","volume":"6","author":"Mascarenhas","year":"2022","journal-title":"Blood Adv."},{"key":"B137","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.exphem.2005.09.016","article-title":"MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8+ autologous T lymphocytes","volume":"34","author":"Mayr","year":"2006","journal-title":"Exp. Hematol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.4049\/jimmunol.121.6.2228","article-title":"Autoantibody to a nuclear antigen in proliferating cells","volume":"121","author":"Miyachi","year":"1978","journal-title":"J. Immunol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.bmc.2015.11.043","article-title":"8-Hydroxyquinoline-based inhibitors of the Rce1 protease disrupt Ras membrane localization in human cells","volume":"24","author":"Mohammed","year":"2016","journal-title":"Bioorg Med. Chem."},{"key":"B140","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.cell.2007.05.003","article-title":"PCNA, the maestro of the replication fork","volume":"129","author":"Moldovan","year":"2007","journal-title":"Cell"},{"key":"B141","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ccell.2024.02.012","article-title":"Exploiting the therapeutic implications of KRAS inhibition on tumor immunity","volume":"42","author":"Molina-Arcas","year":"2024","journal-title":"Cancer Cell"},{"key":"B142","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/0092-8674(92)90644-r","article-title":"The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation","volume":"69","author":"Momand","year":"1992","journal-title":"Cell"},{"key":"B143","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1093\/nar\/26.15.3453","article-title":"The MDM2 gene amplification database","volume":"26","author":"Momand","year":"1998","journal-title":"Nucleic Acids Res."},{"key":"B144","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s10637-022-01253-3","article-title":"Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study","volume":"40","author":"Moschos","year":"2022","journal-title":"Invest New Drugs"},{"key":"B146","doi-asserted-by":"publisher","first-page":"e70430","DOI":"10.1371\/journal.pone.0070430","article-title":"Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells","volume":"8","author":"M\u00fcller","year":"2013","journal-title":"PLoS One"},{"key":"B147","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/147323000703500208","article-title":"Immunohistochemical analysis of PCNA, Ki67 and p53 in nasal polyposis and sinonasal inverted papillomas","volume":"35","author":"Mumbuc","year":"2007","journal-title":"J. Int. Med. Res."},{"key":"B148","doi-asserted-by":"publisher","first-page":"254","DOI":"10.7555\/JBR.27.20130030","article-title":"The MDM2-p53 pathway revisited","volume":"27","author":"Nag","year":"2013","journal-title":"J. Biomed. Res."},{"key":"B149","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2174\/09298673113206660325","article-title":"Targeting MDM2-p53 interaction for cancer therapy: are we there yet?","volume":"21","author":"Nag","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"B150","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev-pharmtox-022823-113946","article-title":"Direct K-Ras inhibitors to treat cancers: progress, new insights, and approaches to treat resistance","volume":"64","author":"Nussinov","year":"2024","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/358080a0","article-title":"Amplification of a gene encoding a p53-associated protein in human sarcomas","volume":"358","author":"Oliner","year":"1992","journal-title":"Nature"},{"key":"B152","doi-asserted-by":"publisher","first-page":"a026336","DOI":"10.1101\/cshperspect.a026336","article-title":"The role of MDM2 amplification and overexpression in tumorigenesis","volume":"6","author":"Oliner","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B153","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1158\/1541-7786.1.2.1","article-title":"MDM2 and prognosis","volume":"2","author":"Onel","year":"2004","journal-title":"Mol. Cancer Res."},{"key":"B154","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"B155","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1200\/JCO.21.02752","article-title":"First-in-Human phase I\/IB dose-finding Study of Adagrasib (MRTX849) in patients with advanced KRASG12C solid tumors (KRYSTAL-1)","volume":"40","author":"Ou","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"44299","DOI":"10.18632\/oncotarget.9996","article-title":"A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth","volume":"7","author":"Pan","year":"2016","journal-title":"Oncotarget"},{"key":"B157","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.ccell.2017.11.003","article-title":"Synthetic lethality of combined Bcl-2 inhibition and p53 activation in AML: mechanisms and superior antileukemic efficacy","volume":"32","author":"Pan","year":"2017","journal-title":"Cancer Cell"},{"key":"B158","doi-asserted-by":"publisher","first-page":"116771","DOI":"10.1016\/j.ejmech.2024.116771","article-title":"Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers","volume":"277","author":"Pandey","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"B159","doi-asserted-by":"publisher","first-page":"28311","DOI":"10.1021\/acsomega.5c03331","article-title":"PCNA in Pan-Cancer: a prognostic biomarker unveiled through a Data-Driven, multidimensional analysis of transcriptomics, immunity, and functional profiling","volume":"10","author":"Pandit","year":"2025","journal-title":"ACS Omega"},{"key":"B160","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1126\/science.aam7622","article-title":"Drugging RAS: know the enemy","volume":"355","author":"Papke","year":"2017","journal-title":"Science"},{"key":"B161","doi-asserted-by":"publisher","first-page":"4580","DOI":"10.1038\/s41467-023-40299-6","article-title":"Cryo-EM structure of a RAS\/RAF recruitment complex","volume":"14","author":"Park","year":"2023","journal-title":"Nat. Commun."},{"key":"B162","doi-asserted-by":"publisher","first-page":"143","DOI":"10.4172\/2169-0138.1000143","article-title":"Synthesis, biological evaluation and modeling studies of new Pyrido[3,4-b]indole derivatives as broad-spectrum potent anticancer agents","volume":"6","author":"Patil","year":"2017","journal-title":"Drug Des."},{"key":"B163","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/s41568-024-00679-6","article-title":"Combinatorial strategies to target RAS-driven cancers","volume":"24","author":"Perurena","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"B164","doi-asserted-by":"publisher","first-page":"106222","DOI":"10.1016\/j.leukres.2019.106222","article-title":"Evaluating dose-limiting toxicities of MDM2 inhibitors in patients with solid organ and hematologic malignancies: a systematic review of the literature","volume":"86","author":"Pi","year":"2019","journal-title":"Leuk. Res."},{"key":"B165","doi-asserted-by":"publisher","first-page":"4923","DOI":"10.1007\/s00018-019-03150-0","article-title":"The PCNA interaction motifs revisited: thinking outside the PIP-box","volume":"76","author":"Prestel","year":"2019","journal-title":"Cell Mol. Life Sci."},{"key":"B166","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The frequency of ras mutations in cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res."},{"key":"B167","doi-asserted-by":"publisher","first-page":"1164535","DOI":"10.3389\/fonc.2023.1164535","article-title":"Tumor heterogeneity: preclinical models, emerging technologies, and future applications","volume":"13","author":"Proietto","year":"2023","journal-title":"Front. Oncol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"14289","DOI":"10.1074\/jbc.M112.353201","article-title":"Identification of small molecule proliferating cell nuclear antigen (PCNA) inhibitor that disrupts interactions with PIP-box proteins and inhibits DNA replication","volume":"287","author":"Punchihewa","year":"2012","journal-title":"J. Biol. Chem."},{"key":"B169","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","article-title":"The current state of the art and future trends in RAS-targeted cancer therapies","volume":"19","author":"Punekar","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B170","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.3390\/cells9071592","article-title":"Targeted brain tumor therapy by inhibiting the MDM2 oncogene: in vitro and in vivo antitumor activity and mechanism of action","volume":"9","author":"Punganuru","year":"2020","journal-title":"Cells"},{"key":"B171","doi-asserted-by":"publisher","first-page":"102238","DOI":"10.1016\/j.ctrv.2021.102238","article-title":"NRAS mutant melanoma: towards better therapies","volume":"99","author":"Randic","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"B172","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S1470-2045(12)70474-6","article-title":"Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study","volume":"13","author":"Ray-Coquard","year":"2012","journal-title":"Lancet Oncol."},{"key":"B173","doi-asserted-by":"publisher","first-page":"6332","DOI":"10.1021\/jm500627s","article-title":"Discovery of a small molecule MDM2 inhibitor (AMG 232) for treating cancer","volume":"57","author":"Rew","year":"2014","journal-title":"J. Med. Chem."},{"key":"B174","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","article-title":"Diminished efficacy of programmed Death-(Ligand)1 inhibition in STK11- and KEAP1-Mutant lung adenocarcinoma is affected by KRAS mutation status","volume":"17","author":"Ricciuti","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"B175","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ccr.2006.10.010","article-title":"Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo","volume":"10","author":"Ringshausen","year":"2006","journal-title":"Cancer Cell"},{"key":"B176","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.molcel.2016.04.033","article-title":"Chromatin-Bound MDM2 regulates serine metabolism and redox homeostasis independently of p53","volume":"62","author":"Riscal","year":"2016","journal-title":"Mol. Cell"},{"key":"B177","doi-asserted-by":"publisher","first-page":"5693","DOI":"10.4049\/jimmunol.1102267","article-title":"Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44","volume":"187","author":"Rosental","year":"2011","journal-title":"J. Immunol."},{"key":"B178","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41571-018-0105-0","article-title":"Therapeutic strategies to target RAS-mutant cancers","volume":"15","author":"Ryan","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B179","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1158\/2159-8290.CD-24-0139","article-title":"The Pan-RAF-MEK nondegrading molecular glue NST-628 is a potent and brain-penetrant inhibitor of the RAS-MAPK pathway with activity across diverse RAS- and RAF-Driven cancers","volume":"14","author":"Ryan","year":"2024","journal-title":"Cancer Discov."},{"key":"B180","doi-asserted-by":"publisher","first-page":"16288","DOI":"10.1021\/ja044883w","article-title":"Use of a retroinverso p53 peptide as an inhibitor of MDM2","volume":"126","author":"Sakurai","year":"2004","journal-title":"J. Am. Chem. Soc."},{"key":"B181","doi-asserted-by":"publisher","first-page":"5236","DOI":"10.1158\/1078-0432.CCR-21-0715","article-title":"Phase 1 trial of ALRN-6924, a dual inhibitor of MDMX and MDM2, in patients with solid tumors and Lymphomas Bearing Wild-Type TP53","volume":"27","author":"Saleh","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B182","doi-asserted-by":"publisher","first-page":"147952","DOI":"10.1016\/j.gene.2023.147952","article-title":"Whole exome sequencing uncovers HRAS mutations as potential mediators of resistance to metronomic chemotherapy","volume":"893","author":"Sambath","year":"2024","journal-title":"Gene"},{"key":"B183","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1002\/stem.753","article-title":"MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis","volume":"29","author":"Sato","year":"2011","journal-title":"Stem Cells"},{"key":"B184","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1038\/onc.2015.375","article-title":"Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma","volume":"35","author":"Schabath","year":"2016","journal-title":"Oncogene"},{"key":"B185","doi-asserted-by":"publisher","first-page":"4058","DOI":"10.1158\/0008-5472.CAN-22-1731","article-title":"Genomic landscapes and hallmarks of mutant RAS in human cancers","volume":"82","author":"Scharpf","year":"2022","journal-title":"Cancer Res."},{"key":"B186","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s12185-022-03464-z","article-title":"Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia","volume":"117","author":"Sekiguchi","year":"2023","journal-title":"Int. J. Hematol."},{"key":"B187","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1038\/sj.bjc.6600297","article-title":"The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells","volume":"86","author":"Senaratne","year":"2002","journal-title":"Br. J. Cancer"},{"key":"B188","doi-asserted-by":"publisher","first-page":"107092","DOI":"10.1016\/j.bioorg.2023.107092","article-title":"Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions","volume":"144","author":"Shang","year":"2024","journal-title":"Bioorg. Chem."},{"key":"B189","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.3389\/fimmu.2018.01114","article-title":"NKp44-Derived peptide binds proliferating cell nuclear antigen and mediates tumor cell death","volume":"9","author":"Shemesh","year":"2018","journal-title":"Front. Immunol."},{"key":"B190","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1096\/fj.201601240R","article-title":"Cooperation of Musashi-2, Numb, MDM2, and P53 in drug resistance and malignant biology of pancreatic cancer","volume":"31","author":"Sheng","year":"2017","journal-title":"FASEB J."},{"key":"B267","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1093\/carcin\/bgw088","article-title":"Dual targeting of MDM2 with a novel small-molecule inhibitor overcomes TRAIL resistance in cancer","volume":"37","author":"Singh","year":"2016","journal-title":"Carcinogenesis"},{"key":"B191","doi-asserted-by":"publisher","first-page":"110505","DOI":"10.1016\/j.cellsig.2022.110505","article-title":"RAS: circuitry and therapeutic targeting","volume":"101","author":"Singh","year":"2023","journal-title":"Cell Signal"},{"key":"B192","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","article-title":"Targeting KRAS in cancer","volume":"30","author":"Singhal","year":"2024","journal-title":"Nat. Med."},{"key":"B193","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B194","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3390\/genes9080416","article-title":"Maneuvers on PCNA rings during DNA replication and repair","volume":"9","author":"Slade","year":"2018","journal-title":"Genes (Basel)"},{"key":"B195","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B196","doi-asserted-by":"publisher","first-page":"7773","DOI":"10.1093\/nar\/16.16.7773","article-title":"KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas","volume":"16","author":"Smit","year":"1988","journal-title":"Nucleic Acids Res."},{"key":"B197","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1124\/mol.114.093211","article-title":"A peptide mimicking a region in proliferating cell nuclear antigen specific to key protein interactions is cytotoxic to breast cancer","volume":"87","author":"Smith","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"B198","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.omto.2020.03.025","article-title":"Molecular targeting of cancer-associated PCNA interactions in pancreatic ductal adenocarcinoma using a cell-penetrating peptide","volume":"17","author":"Smith","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"B199","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/bs.apha.2024.04.002","article-title":"Targeting proliferating cell nuclear antigen (PCNA) for cancer therapy","volume":"100","author":"S\u00f8gaard","year":"2024","journal-title":"Adv. Pharmacol."},{"key":"B200","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1158\/1078-0432.CCR-21-1295","article-title":"Results from a first-in-human phase I Study of Siremadlin (HDM201) in patients with advanced wild-type TP53 solid tumors and acute leukemia","volume":"28","author":"Stein","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"B201","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ccr.2014.02.017","article-title":"Dragging ras back in the ring","volume":"25","author":"Stephen","year":"2014","journal-title":"Cancer Cell"},{"key":"B202","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1093\/aob\/mcq243","article-title":"Proliferating cell nuclear antigen (PCNA): a key factor in DNA replication and cell cycle regulation","volume":"107","author":"Strzalka","year":"2011","journal-title":"Ann. Bot."},{"key":"B203","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.3390\/jcm12113638","article-title":"MDM2 implications for potential molecular pathogenic therapies of soft-tissue tumors","volume":"12","author":"Sun","year":"2023","journal-title":"J. Clin. Med."},{"key":"B204","doi-asserted-by":"publisher","first-page":"4529","DOI":"10.2174\/0929867323666160926150820","article-title":"MDM2 increases drug resistance in cancer cells by inducing EMT independent of p53","volume":"23","author":"Sun","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"B205","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s10020-020-00193-z","article-title":"Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC","volume":"26","author":"Sun","year":"2020","journal-title":"Mol. Med."},{"key":"B206","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12929-024-01004-x","article-title":"Targeting MDM2 in malignancies is a promising strategy for overcoming resistance to anticancer immunotherapy","volume":"31","author":"Sun","year":"2024","journal-title":"J. Biomed. Sci."},{"key":"B207","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1124\/mol.112.077735","article-title":"Small-molecule targeting of proliferating cell nuclear antigen chromatin association inhibits tumor cell growth","volume":"81","author":"Tan","year":"2012","journal-title":"Mol. Pharmacol."},{"key":"B208","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.cell.2016.03.029","article-title":"Oncogenic KRAS regulates tumor cell signaling via stromal reciprocation","volume":"165","author":"Tape","year":"2016","journal-title":"Cell"},{"key":"B209","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.3390\/ijms25042366","article-title":"NTRK therapy among different types of cancers, review and future perspectives","volume":"25","author":"Theik","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B210","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1073\/pnas.0507493103","article-title":"Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy","volume":"103","author":"Tovar","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B211","doi-asserted-by":"publisher","first-page":"1006959","DOI":"10.3389\/fonc.2022.1006959","article-title":"Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma","volume":"12","author":"Traweek","year":"2022","journal-title":"Front. Oncol."},{"key":"B212","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/modpathol.3800484","article-title":"MDM2 protein expression is a negative prognostic marker in breast carcinoma","volume":"19","author":"Turbin","year":"2006","journal-title":"Mod. Pathol."},{"key":"B213","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1080\/13543776.2024.2419836","article-title":"An update patent review of MDM2-p53 interaction inhibitors (2019-2023)","volume":"34","author":"Twarda-Clapa","year":"2024","journal-title":"Expert Opin. Ther. Pat."},{"key":"B214","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.semcancer.2021.05.010","article-title":"RAF-MEK-ERK pathway in cancer evolution and treatment","volume":"85","author":"Ullah","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"B215","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In vivo activation of the p53 pathway by small-molecule antagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science"},{"key":"B216","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1021\/ml4000657","article-title":"Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development","volume":"4","author":"Vu","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"B217","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nrc3430","article-title":"MDM2, MDMX and p53 in oncogenesis and cancer therapy","volume":"13","author":"Wade","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"B218","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1021\/acs.jmedchem.4c00526","article-title":"Targeting the \u201cUndruggable\u201d: Small-Molecule inhibitors of Proliferating Cell Nuclear Antigen (PCNA) in the spotlight in cancer therapy","volume":"68","author":"Wang","year":"2025","journal-title":"J. Med. Chem."},{"key":"B219","doi-asserted-by":"publisher","first-page":"18678","DOI":"10.1074\/jbc.M801855200","article-title":"A small molecule inhibitor of isoprenylcysteine carboxymethyltransferase induces autophagic cell death in PC3 prostate cancer cells","volume":"283","author":"Wang","year":"2008","journal-title":"J. Biol. Chem."},{"key":"B220","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.1158\/1078-0432.CCR-08-2689","article-title":"In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues","volume":"15","author":"Wang","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"B221","doi-asserted-by":"publisher","first-page":"5855","DOI":"10.1158\/0008-5472.CAN-14-0799","article-title":"SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression","volume":"74","author":"Wang","year":"","journal-title":"Cancer Res."},{"key":"B222","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.1038\/ncomms6086","article-title":"The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models","volume":"5","author":"Wang","year":"","journal-title":"Nat. Commun."},{"key":"B223","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1053\/j.gastro.2014.07.001","article-title":"Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice","volume":"147","author":"Wang","year":"","journal-title":"Gastroenterology"},{"key":"B224","doi-asserted-by":"publisher","first-page":"5656","DOI":"10.1158\/0008-5472.CAN-17-3939","article-title":"Discovery and characterization of dual inhibitors of MDM2 and NFAT1 for pancreatic cancer therapy","volume":"78","author":"Wang","year":"2018","journal-title":"Cancer Res."},{"key":"B225","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.ejmech.2019.05.046","article-title":"Development of selective small molecule MDM2 degraders based on nutlin","volume":"176","author":"Wang","year":"","journal-title":"Eur. J. Med. Chem."},{"key":"B226","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.canlet.2019.114429","article-title":"MDM2-NFAT1 dual inhibitor, MA242: effective against hepatocellular carcinoma, independent of p53","volume":"459","author":"Wang","year":"","journal-title":"Cancer Lett."},{"key":"B227","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.gendis.2019.06.001","article-title":"A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance","volume":"6","author":"Wang","year":"","journal-title":"Genes Dis."},{"key":"B228","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.3390\/cancers12123651","article-title":"Targeting MDM2 for neuroblastoma therapy: in vitro and in vivo anticancer activity and mechanism of action","volume":"12","author":"Wang","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B229","doi-asserted-by":"publisher","first-page":"113425","DOI":"10.1016\/j.ejmech.2021.113425","article-title":"Development of MDM2 degraders based on ligands derived from Ugi reactions: lessons and discoveries","volume":"219","author":"Wang","year":"","journal-title":"Eur. J. Med. Chem."},{"key":"B230","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1158\/0008-5472.CAN-20-0189","article-title":"Inhibition of MDM2 promotes antitumor responses in p53 wild-type cancer cells through their interaction with the immune and stromal microenvironment","volume":"81","author":"Wang","year":"","journal-title":"Cancer Res."},{"key":"B231","doi-asserted-by":"publisher","first-page":"109537","DOI":"10.1016\/j.celrep.2021.109537","article-title":"Evading immune surveillance via tyrosine phosphorylation of nuclear PCNA","volume":"36","author":"Wang","year":"","journal-title":"Cell Rep."},{"key":"B232","doi-asserted-by":"publisher","first-page":"5679","DOI":"10.3390\/ijms23105679","article-title":"The functions of PCNA in tumor stemness and invasion","volume":"23","author":"Wang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B233","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1124\/pharmrev.123.001026","article-title":"MDM2 inhibitors for cancer therapy: the past, present, and future","volume":"76","author":"Wang","year":"","journal-title":"Pharmacol. Rev."},{"key":"B234","doi-asserted-by":"publisher","first-page":"18865","DOI":"10.1021\/acs.jmedchem.4c01228","article-title":"Design of Murine double minute 2 proteolysis targeting chimera degraders with a Built-In tumor-targeting ability","volume":"67","author":"Wang","year":"","journal-title":"J. Med. Chem."},{"key":"B235","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s10555-025-10243-9","article-title":"Advancements in gene therapies targeting mutant KRAS in cancers","volume":"44","author":"Wang","year":"2025","journal-title":"Cancer Metastasis Rev."},{"key":"B236","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/s0960-9822(95)00058-3","article-title":"A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigen","volume":"5","author":"Warbrick","year":"1995","journal-title":"Curr. Biol."},{"key":"B237","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1309\/AJCPLYU89XHSNHQO","article-title":"MDM2 copy numbers in well-differentiated and dedifferentiated liposarcoma: characterizing progression to high-grade tumors","volume":"141","author":"Ware","year":"2014","journal-title":"Am. J. Clin. Pathol."},{"key":"B238","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/onc.2012.605","article-title":"Knockdown of RNF2 induces apoptosis by regulating MDM2 and p53 stability","volume":"33","author":"Wen","year":"2014","journal-title":"Oncogene"},{"key":"B239","doi-asserted-by":"publisher","first-page":"e29244","DOI":"10.1002\/jmv.29244","article-title":"The potential of PCNA inhibition as a therapeutic strategy in cervical cancer","volume":"95","author":"Wendel","year":"2023","journal-title":"J. Med. Virol."},{"key":"B240","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1158\/1535-7163.MCT-14-1056-T","article-title":"Small molecule inhibition of MDM2-p53 interaction augments radiation response in human tumors","volume":"14","author":"Werner","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"B241","doi-asserted-by":"publisher","first-page":"14459","DOI":"10.1074\/jbc.272.22.14459","article-title":"K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors","volume":"272","author":"Whyte","year":"1997","journal-title":"J. Biol. Chem."},{"key":"B242","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.molcel.2015.12.008","article-title":"MDM2 Associates with Polycomb repressor Complex 2 and enhances stemness-promoting chromatin modifications independent of p53","volume":"61","author":"Wienken","year":"2016","journal-title":"Mol. Cell"},{"key":"B243","doi-asserted-by":"publisher","first-page":"4336","DOI":"10.1073\/pnas.0408107102","article-title":"A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells","volume":"102","author":"Winter-Vann","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B244","doi-asserted-by":"publisher","first-page":"1223433","DOI":"10.3389\/fimmu.2023.1223433","article-title":"Small molecular inhibitors for KRAS-mutant cancers","volume":"14","author":"Wu","year":"2023","journal-title":"Front. Immunol."},{"key":"B245","doi-asserted-by":"publisher","first-page":"1418469","DOI":"10.3389\/fphar.2024.1418469","article-title":"A real-world pharmacovigilance study of KRAS G12C mutation inhibitors based on the food and drug administration adverse event reporting system","volume":"15","author":"Wu","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B246","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1158\/2159-8290.CD-24-0217","article-title":"Efficacy and safety of adagrasib plus cetuximab in patients with KRASG12C-Mutated metastatic colorectal cancer","volume":"14","author":"Yaeger","year":"2024","journal-title":"Cancer Discov."},{"key":"B247","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1111\/cas.16160","article-title":"Microsatellite instability: a 2024 update","volume":"115","author":"Yamamoto","year":"2024","journal-title":"Cancer Sci."},{"key":"B248","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13045-024-01631-9","article-title":"RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms","volume":"17","author":"Yang","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"B249","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/cac2.12377","article-title":"Targeting RAS mutants in malignancies: successes, failures, and reasons for hope","volume":"43","author":"Yang","year":"","journal-title":"Cancer Commun. (Lond)"},{"key":"B250","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1158\/1538-7445.am2023-1598","article-title":"Abstract 1598: RM-046, a first-in-class, mutant-selective, and oral KRASQ61H(ON) inhibitor that drives tumor regression in preclinical models and validates KRASQ61H as a therapeutic target","volume":"83","author":"Yang","year":"","journal-title":"Cancer Res."},{"key":"B251","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12935-024-03356-8","article-title":"MDM2: current research status and prospects of tumor treatment","volume":"24","author":"Yao","year":"2024","journal-title":"Cancer Cell Int."},{"key":"B252","doi-asserted-by":"publisher","first-page":"e19755","DOI":"10.1097\/MD.0000000000019755","article-title":"Clinical significance of high expression of proliferating cell nuclear antigen in non-small cell lung cancer","volume":"99","author":"Ye","year":"2020","journal-title":"Med. Baltim."},{"key":"B253","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13046-018-0765-8","article-title":"A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma","volume":"37","author":"Yi","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B254","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.canlet.2020.09.023","article-title":"Targeting the p53-MDM2 pathway for neuroblastoma therapy: rays of hope","volume":"496","author":"Zafar","year":"2021","journal-title":"Cancer Lett."},{"key":"B255","doi-asserted-by":"publisher","first-page":"101279","DOI":"10.1016\/j.gendis.2024.101279","article-title":"MDM2 inhibitors in cancer immunotherapy: current status and perspective","volume":"11","author":"Zeng","year":"2024","journal-title":"Genes Dis."},{"key":"B256","doi-asserted-by":"publisher","first-page":"7238","DOI":"10.1038\/sj.onc.1208814","article-title":"Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway","volume":"24","author":"Zhang","year":"2005","journal-title":"Oncogene"},{"key":"B257","doi-asserted-by":"publisher","first-page":"532403","DOI":"10.3389\/fonc.2020.532403","article-title":"Molecular profiling-based precision medicine in cancer: a review of Current evidence and challenges","volume":"10","author":"Zhang","year":"2020","journal-title":"Front. Oncol."},{"key":"B258","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.7150\/ijbs.64628","article-title":"Post-Translational modifications of PCNA in control of DNA synthesis and DNA damage tolerance-the implications in carcinogenesis","volume":"17","author":"Zhang","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"B259","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.62347\/BRTO3272","article-title":"Unveiling the nexus of p53 and PD-L1: insights into immunotherapy resistance mechanisms in hepatocellular carcinoma","volume":"15","author":"Zhang","year":"2025","journal-title":"Am. J. Cancer Res."},{"key":"B260","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1158\/1535-7163.MCT-10-0778","article-title":"Targeting tyrosine phosphorylation of PCNA inhibits prostate cancer growth","volume":"10","author":"Zhao","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"B261","doi-asserted-by":"publisher","first-page":"540238","DOI":"10.3389\/fonc.2020.540238","article-title":"The coexistence of genetic mutations in thyroid carcinoma predicts histopathological factors associated with a poor prognosis: a systematic review and network meta-analysis","volume":"10","author":"Zhao","year":"2020","journal-title":"Front. Oncol."},{"key":"B262","doi-asserted-by":"publisher","first-page":"795","DOI":"10.32604\/or.2025.057317","article-title":"p53: a player in the tumor microenvironment","volume":"33","author":"Zhao","year":"2025","journal-title":"Oncol. Res."},{"key":"B263","doi-asserted-by":"publisher","first-page":"1038069","DOI":"10.1155\/2019\/1038069","article-title":"GTSE1, CDC20, PCNA, and MCM6 synergistically affect regulations in cell cycle and indicate poor prognosis in liver cancer","volume":"2019","author":"Zheng","year":"2019","journal-title":"Anal. Cell Pathol. (Amst)"},{"key":"B264","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.3390\/biom11101439","article-title":"Lipid profiles of RAS nanoclusters regulate RAS function","volume":"11","author":"Zhou","year":"2021","journal-title":"Biomolecules"},{"key":"B265","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41590-021-00888-3","article-title":"The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity","volume":"22","author":"Zhou","year":"","journal-title":"Nat. Immunol."},{"key":"B266","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1158\/2159-8290.CD-20-1741","article-title":"Pharmacologic activation of p53 triggers viral mimicry response thereby abolishing tumor immune evasion and promoting Antitumor immunity","volume":"11","author":"Zhou","year":"","journal-title":"Cancer Discov."},{"key":"B268","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.21037\/atm-21-1948","article-title":"A narrative review of tumor heterogeneity and challenges to tumor drug therapy","volume":"9","author":"Zhu","year":"2021","journal-title":"Ann. Transl. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1663766\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T05:43:15Z","timestamp":1760506995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1663766\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":268,"alternative-id":["10.3389\/fphar.2025.1663766"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1663766","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"article-number":"1663766"}}